Dyadic Sees $500K Milestone, Eyes Commercialization Push Through 2026

Dyadic International anticipates reaching a $500,000 milestone and aims for commercialization ramp through 2026. The company has shifted its focus from platform-focused R&D to commercially-driven biotechnology business, with a new emphasis on competition and growth.

Dyadic International, Inc., a global biotechnology company, announced its financial results for the second quarter of 2025, highlighting a pivotal shift in its operational strategy. The company, now rebranded as Dyadic Applied BioSolutions, has transitioned from a technology development organization to a market-facing, revenue-focused biotechnology company. This strategic realignment is reflected in its financial performance and recent company developments.

Financial Highlights

As of June 30, 2025, Dyadic reported a cash position of approximately $7.3 million, compared to $9.3 million as of December 31, 2024 [1]. The company closed a $5.3 million equity offering on August 1, 2025, which it plans to use for working capital and general corporate purposes, including product development and sales and marketing [1].

Total revenue for the three months ended June 30, 2025, increased to $967,000, compared to $386,000 for the same period a year ago. The increase was driven by milestone revenue from the Inzymes Agreement and grant revenue from the Gates Foundation and CEPI [1].

Research and development expenses for the three months ended June 30, 2025, increased to $629,000, reflecting a rise in the number of active internal research initiatives [1]. General and administrative expenses decreased by 10.6% to $1,437,000, primarily due to reductions in business development and investor relations expenses, accounting and legal expenses, insurance expenses, and management incentives [1].

Recent Company Developments

Dyadic has achieved key development and commercial milestones in life sciences and nutrition markets. In partnership with Proliant Health and Biologicals, Dyadic is advancing toward an expected commercial launch in 2025 of animal-free serum albumin for use in cell culture, diagnostics, and vaccine stabilization. The company has received $1.0 million in milestone payments to date, with additional payments and royalties tied to commercial success [1].

Dyadic's animal-free transferrin has demonstrated equivalent performance to leading recombinant reference standards in cell proliferation testing. Sampling and validation for diagnostic and research use is actively underway in Q3 2025 [1].

The company's recombinant Fibroblast Growth Factor (FGF) has demonstrated comparable performance to reference standards in supporting animal muscle cell growth. Efforts are underway to improve productivity, with additional characterization and validation ongoing [1].

Dyadic is developing and validating prototypes for four additional enzymes, including RNase Inhibitors and T7 RNA Polymerase, to support growing demand for DNA/RNA manipulation tools. Initial quality and productivity improvements have shown positive results, with further optimization underway and results expected by late 2025 and into 2026 [1].

Looking Ahead

Dyadic anticipates achieving a $500,000 milestone and aims for commercialization ramp through 2026. The company's strategic shift from platform-focused R&D to a commercially-driven biotechnology business reflects a new emphasis on competition and growth [1].

References

[1] Dyadic International, Inc. (2025). Dyadic Reports Second-Quarter 2025 Financial Results and Highlights of Recent Company Progress. Globe Newswire. Retrieved from [https://www.globenewswire.com/news-release/2025/08/13/3132946/0/en/Dyadic-Reports-Second-Quarter-2025-Financial-Results-and-Highlights-of-Recent-Company-Progress.html](https://www.globenewswire.com/news-release/2025/08/13/3132946/0/en/Dyadic-Reports-Second-Quarter-2025-Financial-Results-and-Highlights-of-Recent-Company-Progress.html)